Who owns SUPERNUS PHARMACEUTICALS, INC. (SUPN)? Elite investor 13F holders

4 tracked elite investors reported holding SUPERNUS PHARMACEUTICALS, INC as of 2026-09-30, including Rubric Capital, Renaissance Technologies LLC, D.E. Shaw, Third Avenue Management. Who bought, trimmed or exited each quarter, with links to the original SEC 13F filings.

4 tracked investors currently reported holding · Latest report period: 2026-09-30 · Health Care · Pharmaceuticals, Biotechnology & Life Sciences

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with…

Reported holders and securities, including exits (up to 20)

Reported holders and securities, including exits (up to 20)
InvestorSecurityInstrumentReport periodFiledValueQuantityUnitsChangeSource
Rubric CapitalSUPERNUS PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:0074884952.00 USD1739892.000000SharesbuyOriginal filing
Renaissance Technologies LLCSUPERNUS PHARMACEUTICALS INCSHARE2026-09-302026-11-12 00:00:0048705011.00 USD1131622.000000SharesreduceOriginal filing
D.E. ShawSUPERNUS PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:0024125211.00 USD560530.000000SharesreduceOriginal filing
Third Avenue ManagementSUPERNUS PHARMACEUTICALS INCSHARE2026-09-302026-11-13 00:00:006763736.00 USD157150.000000SharesaddOriginal filing
Gotham Asset ManagementSUPERNUS PHARMACEUTICALS INCSHARE2026-09-302026-11-16 00:00:000.00 USD0.000000SharesexitedOriginal filing

Public disclosures can be delayed, incomplete, or amended. Report period describes a position date; transaction date describes a reported transaction; filed describes submission. A recent filing or page update does not establish a current holding. A dash means unavailable or not comparable, not zero.

This public summary shows the default reporting scope. Enable JavaScript for interactive filters, charts, and additional rows.

How to read the data · Disclaimer

Read as Markdown